- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 23
The Center for Biosimilars® recaps the top stories for the week of September 23, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 23, 2019.
Number 5: Generium has received approval for the first biosimilar dornase alfa, which treats cystic fibrosis, in Russia.
Number 4: A newly published paper concludes that, as experience and analytical capabilities mature, there will be a reduced requirement for clinical data in biosimilar development.
Number 3: Two biosimilar bills, both with bipartisan sponsors, were unveiled last week.
Number 2: The Committee for Medicinal Products for Human Use issued a positive opinion for Celltrion’s subcutaneously administered biosimilar infliximab for the treatment of rheumatoid arthritis.
Number 1: The FDA has released a new suite of resources to educate patients about biosimilars.
Finally, last week, our e-newsletter asked whether you think that the 2020 launch of authorized generics of 2 of Novo Nordisk’s insulin products will help patients afford their medication.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
